Tethys Bioscience raises $25m to detect diabetes

In conjunction with the deal, Tethys has appointed George Rehm, managing partner of Aeris Capital, to the Tethys board of directors.

Proceeds from the financing will be used to expand the company’s commercialisation of the company’s proprietary PreDx Diabetes Risk Score (DRS) product, a test to help clinicians identify those patients at highest risk of developing type 2 diabetes within the next five years.

George Rehm, managing partner of Aeris Capital, said, “Tethys is breaking new ground in the diabetes field with the PreDx DRS, which will help clinicians to identify patients at severe risk of becoming diabetic, and who are most likely to benefit from focused intervention and disease prevention management. The company’s technology has broad utility in multiple chronic disease areas where early identification and disease prevention programmes have the potential to improve health outcomes and reduce healthcare costs.”

Aeris Capital acts as financial adviser to the investment interests associated with a European family.

Copyright © 2009 AltAssets